Study Title

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Study Details

Description:

This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Sponsor:

Perspective Therapeutics

Contacts:

Markus Puhlmann, MD, MBA

mpuhlmann@perspectivetherapeutics.com

(319) 665-2150

Government Study Link:

NCT05636618 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468